Details for New Drug Application (NDA): 218779
✉ Email this page to a colleague
NDA 218779 describes SELENIOUS ACID, which is a drug marketed by Am Regent and Fresenius Kabi Usa and is included in two NDAs. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the SELENIOUS ACID profile page.
The generic ingredient in SELENIOUS ACID is selenious acid. One supplier is listed for this compound. Additional details are available on the selenious acid profile page.
The generic ingredient in SELENIOUS ACID is selenious acid. One supplier is listed for this compound. Additional details are available on the selenious acid profile page.
Summary for 218779
| Tradename: | SELENIOUS ACID |
| Applicant: | Fresenius Kabi Usa |
| Ingredient: | selenious acid |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML) | ||||
| Approval Date: | Feb 10, 2025 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
